Iovance Biotherapeutics, Inc. (FRA:2LB)
Germany
· Delayed Price · Currency is EUR 1.891
+0.035 (1.91%)
Last updated: Dec 4, 2025, 8:07 AM CET
Iovance Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 250.43 | 164.07 | 1.19 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 175.62% | 13698.99% | - | - | - | - | Upgrade
|
| Cost of Revenue | 198.61 | 124 | 10.76 | - | - | - | Upgrade
|
| Gross Profit | 51.82 | 40.08 | -9.57 | - | - | - | Upgrade
|
| Selling, General & Admin | 158.99 | 153.02 | 106.92 | 104.1 | 83.66 | 60.21 | Upgrade
|
| Research & Development | 306.18 | 282.34 | 344.08 | 294.78 | 259.04 | 201.73 | Upgrade
|
| Operating Expenses | 463.15 | 435.35 | 450.99 | 398.88 | 342.7 | 261.94 | Upgrade
|
| Operating Income | -411.33 | -395.28 | -460.56 | -398.88 | -342.7 | -261.94 | Upgrade
|
| Interest & Investment Income | 10.01 | 10.01 | 9.44 | 3.46 | 6.46 | 4.22 | Upgrade
|
| EBT Excluding Unusual Items | -401.82 | -385.27 | -451.12 | -395.42 | -336.24 | -257.72 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.63 | 10.26 | 3.61 | -0.47 | -6.01 | -1.87 | Upgrade
|
| Pretax Income | -398.33 | -375.01 | -447.52 | -395.89 | -342.25 | -259.58 | Upgrade
|
| Income Tax Expense | -0.7 | -2.83 | -3.48 | - | - | - | Upgrade
|
| Net Income | -397.63 | -372.18 | -444.04 | -395.89 | -342.25 | -259.58 | Upgrade
|
| Net Income to Common | -397.63 | -372.18 | -444.04 | -395.89 | -342.25 | -259.58 | Upgrade
|
| Shares Outstanding (Basic) | 332 | 290 | 235 | 159 | 153 | 138 | Upgrade
|
| Shares Outstanding (Diluted) | 332 | 290 | 235 | 159 | 153 | 138 | Upgrade
|
| Shares Change (YoY) | 19.46% | 23.28% | 47.64% | 3.82% | 10.92% | 11.23% | Upgrade
|
| EPS (Basic) | -1.20 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | Upgrade
|
| EPS (Diluted) | -1.20 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | Upgrade
|
| Free Cash Flow | -351.82 | -364.05 | -384.11 | -313.18 | -265.52 | -251.93 | Upgrade
|
| Free Cash Flow Per Share | -1.06 | -1.26 | -1.63 | -1.97 | -1.73 | -1.82 | Upgrade
|
| Gross Margin | 20.69% | 24.43% | - | - | - | - | Upgrade
|
| Operating Margin | -164.25% | -240.92% | -38734.99% | - | - | - | Upgrade
|
| Profit Margin | -158.78% | -226.84% | -37345.42% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -140.49% | -221.89% | -32305.30% | - | - | - | Upgrade
|
| EBITDA | -375.79 | -362.11 | -439.14 | -389.57 | -339.59 | -260.8 | Upgrade
|
| EBITDA Margin | -150.06% | -220.70% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 35.54 | 33.17 | 21.42 | 9.31 | 3.11 | 1.14 | Upgrade
|
| EBIT | -411.33 | -395.28 | -460.56 | -398.88 | -342.7 | -261.94 | Upgrade
|
| EBIT Margin | -164.25% | -240.92% | - | - | - | - | Upgrade
|
| Revenue as Reported | 250.43 | 164.07 | 1.19 | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.